VEGF-A

Assets acting on this target.

Class
VEGF-A inhibitor
Pathway
VEGF-A / VEGFR angiogenic signaling

VEGF-A (vascular endothelial growth factor A) is a signaling protein that binds receptors on blood vessel lining cells, driving new vessel formation and increasing vessel permeability. In the eye, excessive VEGF-A activity underlies several blinding conditions, including wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy, where abnormal, leaky vessels grow beneath or within the retina and cause fluid accumulation, hemorrhage, and progressive vision loss. Neutralizing VEGF-A reduces this abnormal vascularization and vascular leakage, which is why anti-VEGF therapy has become a mainstay of retinal disease management. Conventional treatment requires repeated intraocular injections of antibody-based drugs because these proteins are cleared over weeks to months. Gene therapy approaches address this limitation by delivering, via a single injection, a viral vector containing genetic instructions for retinal cells to continuously produce their own anti-VEGF protein, in this case a secreted antibody fragment. The goal is durable, self-sustaining suppression of VEGF-A activity within the eye, potentially reducing the treatment burden associated with chronic dosing while achieving the same underlying biological effect as injected anti-VEGF biologics.

By indication

Related mechanisms

VEGF-A drugs compared

39 drugs, stage by indication
39 drugs acting on VEGF-A: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
AfliberceptEyleaBayer, Regeneron Pharmaceuticalsfusion proteinApprovedApproved in Age-Related Macular Degeneration; Approved in Diabetic Macular Edema; Approved in Wet Age-Related Macular Degeneration
aflibercept-abzv (Enzeevu)EnzeevuSandoz Group AGfusion proteinApprovedApproved in Age-Related Macular Degeneration; Approved in Diabetic Macular Edema
aflibercept-ayyh (Pavblu)PavbluAmgenfusion proteinApprovedApproved in Age-Related Macular Degeneration; Approved in Diabetic Macular Edema; Approved in Wet Age-Related Macular Degeneration
aflibercept-boav (Eydenzelt)EydenzeltCelltrionfusion proteinApprovedApproved in Age-Related Macular Degeneration; Approved in Diabetic Macular Edema; Approved in Wet Age-Related Macular Degeneration
aflibercept-jbvf (Yesafili)YesafiliBiocon Biologicsfusion proteinApprovedApproved in Age-Related Macular Degeneration; Approved in Diabetic Macular Edema; Approved in Wet Age-Related Macular Degeneration
aflibercept-mrbb (Ahzantive)AhzantiveFormycon AG, Klinge Biopharma GmbH, Valorum Biologics LLCfusion proteinApprovedApproved in Age-Related Macular Degeneration; Approved in Diabetic Macular Edema; Approved in Wet Age-Related Macular Degeneration
aflibercept-yszy (Opuviz)OpuvizHarrow, Inc., Samsung Bioepisfusion proteinApprovedApproved in Age-Related Macular Degeneration; Approved in Diabetic Macular Edema; Approved in Wet Age-Related Macular Degeneration
Alymsys (bevacizumab-maly)Amneal Pharmaceuticalsmonoclonal antibodyApprovedApproved in Advanced Metastatic Colorectal Cancer; Approved in Cervical Cancer; Approved in Colorectal Cancer; Approved in Glioblastoma; Approved in Metastatic Colorectal Cancer; Approved in Non-Small Cell Lung Cancer; Approved in Recurrent Glioblastoma; Approved in Renal Cell Carcinoma
BAT1706AvziviBeOne Medicines, Bio-Thera Solutions, Sandoz Group AGmonoclonal antibodyApprovedApproved in Cervical Cancer; Approved in Colorectal Cancer; Approved in Glioblastoma; Approved in Non-Small Cell Lung Cancer; Approved in Ovarian Cancer; Approved in Renal Cell Carcinoma
BevacizumabRochemonoclonal antibodyApprovedApproved in Cervical Cancer; Approved in Colorectal Cancer; Approved in Hepatocellular Carcinoma; Approved in Metastatic Colorectal Cancer; Approved in Non-Small Cell Lung Cancer; Approved in Ovarian Cancer; Approved in Recurrent Glioblastoma; Approved in Renal Cell Carcinoma
bevacizumab-awwbMVASIAmgen, Daiichi Sankyomonoclonal antibodyApprovedApproved in Advanced Metastatic Colorectal Cancer; Approved in Cervical Cancer; Approved in Colorectal Cancer; Approved in Metastatic Colorectal Cancer; Approved in Non-Small Cell Lung Cancer; Approved in Recurrent Glioblastoma; Approved in Renal Cell Carcinoma
Brolucizumab-DbllChina Medical System, Novartisantibody fragment (scFv)ApprovedApproved in Age-Related Macular Degeneration; Approved in Diabetic Macular Edema; Approved in Wet Age-Related Macular Degeneration
Jobevne (bevacizumab-nwgd)Biocon, Biocon Biologicsmonoclonal antibodyApprovedApproved in Advanced Metastatic Colorectal Cancer; Approved in Cervical Cancer; Approved in Colorectal Cancer; Approved in Metastatic Colorectal Cancer; Approved in Non-Small Cell Lung Cancer; Approved in Ovarian Cancer; Approved in Recurrent Glioblastoma; Approved in Renal Cell Carcinoma
RanibizumabLucentisNovartis, Rocheantibody fragmentApprovedApproved in Age-Related Macular Degeneration; Approved in Diabetic Macular Edema; Approved in Wet Age-Related Macular Degeneration
ranibizumab-eqrn (Cimerli)CimerliSandoz Group AGmonoclonal antibodyApprovedApproved in Age-Related Macular Degeneration; Approved in Diabetic Macular Edema; Approved in Wet Age-Related Macular Degeneration
ranibizumab-hkdz (Ranluspec)RanluspecLupin Limited, Sandoz Group AGmonoclonal antibodyApprovedApproved in Age-Related Macular Degeneration; Approved in Diabetic Macular Edema
ranibizumab-leyk (Nufymco)NufymcoBioeq AG, Formycon AG, Zydus Lifesciencesmonoclonal antibodyApprovedApproved in Age-Related Macular Degeneration; Approved in Diabetic Macular Edema; Approved in Wet Age-Related Macular Degeneration
ranibizumab-nuna (Byooviz)ByoovizHarrow, Inc., Samsung Bioepismonoclonal antibodyApprovedApproved in Age-Related Macular Degeneration; Approved in Wet Age-Related Macular Degeneration
Vegzelma (bevacizumab-adcd)Celltrionmonoclonal antibodyApprovedApproved in Advanced Metastatic Colorectal Cancer; Approved in Cervical Cancer; Approved in Colorectal Cancer; Approved in Metastatic Colorectal Cancer; Approved in Non-Small Cell Lung Cancer; Approved in Ovarian Cancer; Approved in Recurrent Glioblastoma; Approved in Renal Cell Carcinoma
Zirabev (bevacizumab-bvzr)ZirabevPfizermonoclonal antibodyApprovedApproved in Advanced Metastatic Colorectal Cancer; Approved in Cervical Cancer; Approved in Colorectal Cancer; Approved in Metastatic Colorectal Cancer; Approved in Non-Small Cell Lung Cancer; Approved in Recurrent Glioblastoma; Approved in Renal Cell Carcinoma
BAT5906Bio-Thera Solutionsmonoclonal antibodyPhase 3Phase 3 in Age-Related Macular Degeneration
CKD-701LucenbiesChong Kun Dang Pharmaceuticalmonoclonal antibodyPhase 3Phase 3 in Age-Related Macular Degeneration
HD204Intas Pharmaceuticals, Prestige Biopharma Limitedmonoclonal antibodyPhase 3Phase 3 in Non-Small Cell Lung Cancer
HLX04HanbeitaiShanghai Henlius Biotechmonoclonal antibodyPhase 3Phase 3 in Colorectal Cancer; Phase 3 in Non-Small Cell Lung Cancer
HLX04-OEssex Bio-Technology Limited, Shanghai Henlius Biotechmonoclonal antibodyPhase 3Phase 3 in Age-Related Macular Degeneration
IBI305Innovent Biologicsmonoclonal antibodyPhase 3Phase 3 in Non-Small Cell Lung Cancer; Phase 2 in Colorectal Cancer
LY01008Luye Pharma Groupmonoclonal antibodyPhase 3Phase 3 in Non-Small Cell Lung Cancer; Phase 1 in Colorectal Cancer
Ranibizumab (Ximluci)XimluciSTADA Arzneimittel, Xbrane Biopharma ABmonoclonal antibodyPhase 3Phase 3 in Age-Related Macular Degeneration
Surabgene lomparvovecAbbVie, REGENXBIO Inc.AAV gene therapyPhase 3Phase 3 in Age-Related Macular Degeneration
Tarcocimab tedromerKodiak Sciences Inc.monoclonal antibody-biopolymer conjugatePhase 3Phase 3 in Age-Related Macular Degeneration; Phase 3 in Wet Age-Related Macular Degeneration
MW02Mabwell Bioscience, Pyxis Oncologymonoclonal antibodyPhase 2/3Phase 2/3 in Age-Related Macular Degeneration
Ranibizumab (Rimmyrah)RimmyrahQilu Pharmaceuticalmonoclonal antibodyPhase 1Phase 1 in Age-Related Macular Degeneration
Aflibercept (Afiveg)AfivegAlvotech, STADA Arzneimittelfusion proteinStage not recordedNot recorded
Aflibercept (Eyluxvi)EyluxviAlteogen Inc., Biolitec Pharmafusion proteinStage not recordedNot recorded
Aflibercept (Mynzepli)MynzepliAdvanz Pharma, Alvotechfusion proteinStage not recordedNot recorded
Aflibercept (Vgenfli)VgenfliPolpharma S.A., Sam Chun Dang Pharm. Co., Ltd.fusion proteinStage not recordedNot recorded
Ranibizumab (Ranivisio)RanivisioMidas Pharma GmbHmonoclonal antibodyStage not recordedNot recorded
Ranibizumab (Rexatilux)RexatiluxIntas Pharmaceuticalsmonoclonal antibodyStage not recordedNot recorded
TelberminNewron Sweden ABrecombinant proteinDiscontinuedNot recorded

← all mechanisms